Liquidia (LQDA) Net Income towards Common Stockholders (2020 - 2026)
Liquidia (LQDA) recorded quarterly Net Income towards Common Stockholders of $52.9 million in Q1 2026, up 263.33% quarter-over-quarter from $14.6 million in Q4 2025, and up 237.83% on a YoY basis from $15.7 million in Q1 2025.
Liquidia (LQDA) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Liquidia's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at $52.9 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 237.83% year-over-year to $52.9 million; the TTM figure through Mar 2026 stood at $22.3 million (up 116.35% YoY), while the FY2025 annual figure was -$68.9 million, up 46.28% from the prior year.
- Net Income towards Common Stockholders was $52.9 million for Q1 2026 at Liquidia, up from $14.6 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $52.9 million in Q1 2026 to a low of -$41.6 million in Q2 2025.
- Historically, Net Income towards Common Stockholders has averaged -$15.3 million across 5 years, with a median of -$15.8 million in 2023.
- The sharpest annual moves came in 2023 and 2026: Net Income towards Common Stockholders slumped 320.17% in 2023, then jumped 237.83% in 2026.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$6.5 million in 2022, then plunged by 320.17% to -$27.4 million in 2023, then tumbled by 40.29% to -$38.5 million in 2024, then jumped by 137.8% to $14.6 million in 2025, then soared by 263.33% to $52.9 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at $52.9 million (Q1 2026), $14.6 million (Q4 2025), and -$3.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 366.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 1.99 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | -92.12 Mn |
| 10 | Liquidia | 5.74 Bn | 5.52 Bn | 121.79 Mn | 52.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 52.88 Mn |
| Dec 31, 2025 | 14.56 Mn |
| Sep 30, 2025 | -3.53 Mn |
| Jun 30, 2025 | -41.58 Mn |
| Mar 31, 2025 | -38.37 Mn |
| Dec 31, 2024 | -38.51 Mn |
| Sep 30, 2024 | -31.03 Mn |
| Jun 30, 2024 | -28.67 Mn |
| Mar 31, 2024 | -30.08 Mn |
| Dec 31, 2023 | -27.45 Mn |
| Sep 30, 2023 | -15.79 Mn |
| Jun 30, 2023 | -23.52 Mn |
| Mar 31, 2023 | -9.43 Mn |
| Dec 31, 2022 | -6.53 Mn |
| Sep 30, 2022 | -9.09 Mn |
| Jun 30, 2022 | -9.45 Mn |
| Mar 31, 2022 | -14.95 Mn |
| Dec 31, 2021 | -11.56 Mn |
| Sep 30, 2021 | -7.28 Mn |
| Jun 30, 2021 | -6.55 Mn |